{"protocolSection":{"identificationModule":{"nctId":"NCT07020819","orgStudyIdInfo":{"id":"ANX005-GBS-05"},"secondaryIdInfos":[{"id":"2025-522664-32-00","type":"CTIS"}],"organization":{"fullName":"Annexon, Inc.","class":"INDUSTRY"},"briefTitle":"An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)","officialTitle":"An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (GBS) (FORWARD Study)"},"statusModule":{"statusVerifiedDate":"2026-02","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-09-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2028-06-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-06-06","studyFirstSubmitQcDate":"2025-06-06","studyFirstPostDateStruct":{"date":"2025-06-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-02-18","lastUpdatePostDateStruct":{"date":"2026-02-20","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Annexon, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe."},"conditionsModule":{"conditions":["Guillain-Barre Syndrome"],"keywords":["Guillain-Barre Syndrome","GBS","ANX005","Tanruprubart","FORWARD study"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":30,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Tanruprubart","type":"EXPERIMENTAL","description":"Participants will receive a single 30 mg/kg intravenous (IV) infusion of tanruprubart on Day 1.","interventionNames":["Drug: Tanruprubart"]}],"interventions":[{"type":"DRUG","name":"Tanruprubart","description":"Solution for IV infusion.","armGroupLabels":["Tanruprubart"],"otherNames":["ANX005"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Area Under the Tanruprubart Serum Concentration-time Curve to the Last Sample (AUC0-t)","timeFrame":"Up to Day 15"},{"measure":"Observed Time to Maximum Observed Serum Concentration (Cmax) (Tmax) of Tanruprubart","timeFrame":"Up to Day 15"}],"secondaryOutcomes":[{"measure":"Change From Baseline in Free Component of Complement Complex (C1q) Protein Concentration in Serum","timeFrame":"Baseline up to Day 15"},{"measure":"Change from Baseline in Medical Research Council (MRC) Sumscore at Week 1","timeFrame":"Baseline, Week 1"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Diagnosis of GBS according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for GBS.\n* Onset of GBS-related weakness ≤10 days before start of infusion on Day 1\n* GBS-disability score (DS) score of 3, 4, or 5 at screening and before start of infusion on Day 1.\n\nKey Exclusion Criteria:\n\n* Previous or intended treatment with either plasma exchange or IV immunoglobulin for GBS.\n* Diagnosis of a variant of GBS, including Miller Fisher syndrome, Bickerstaff's encephalitis, and overlap syndromes.\n\nOther protocol-defined criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"85 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Study Coordinator","role":"CONTACT","phone":"1-650-822-5500","email":"clinicaltrials@annexonbio.com"}],"overallOfficials":[{"name":"Clinical Trials","affiliation":"Annexon, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"HonorHealth Bob Bové Neuroscience Institute","status":"RECRUITING","city":"Scottsdale","state":"Arizona","zip":"85251","country":"United States","geoPoint":{"lat":33.50921,"lon":-111.89903}},{"facility":"Children's Hospital of Orange County","status":"RECRUITING","city":"Orange","state":"California","zip":"92868","country":"United States","geoPoint":{"lat":33.78779,"lon":-117.85311}},{"facility":"University of California Irvine","status":"RECRUITING","city":"Orange","state":"California","zip":"92868","country":"United States","geoPoint":{"lat":33.78779,"lon":-117.85311}},{"facility":"University of Colorado Hospital","status":"RECRUITING","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"Ochsner LSU Health","status":"RECRUITING","city":"Shreveport","state":"Louisiana","zip":"71101","country":"United States","geoPoint":{"lat":32.52515,"lon":-93.75018}},{"facility":"University Massachusetts Chan Medical School","status":"RECRUITING","city":"Worcester","state":"Massachusetts","zip":"01655","country":"United States","geoPoint":{"lat":42.26259,"lon":-71.80229}},{"facility":"Henry Ford Health","status":"RECRUITING","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Mayo Rochester","status":"RECRUITING","city":"Rochester","state":"Minnesota","zip":"55905","country":"United States","geoPoint":{"lat":44.02163,"lon":-92.4699}},{"facility":"Aarhus University Hospital","status":"RECRUITING","city":"Aarhus","state":"Aarhus N","zip":"8200","country":"Denmark","geoPoint":{"lat":56.15674,"lon":10.21076}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Related Info","url":"https://theforwardstudy.com/"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D020275","term":"Guillain-Barre Syndrome"}],"ancestors":[{"id":"D011129","term":"Polyradiculoneuropathy"},{"id":"D020274","term":"Autoimmune Diseases of the Nervous System"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D003711","term":"Demyelinating Diseases"},{"id":"D011115","term":"Polyneuropathies"},{"id":"D010523","term":"Peripheral Nervous System Diseases"},{"id":"D009468","term":"Neuromuscular Diseases"},{"id":"D001327","term":"Autoimmune Diseases"},{"id":"D007154","term":"Immune System Diseases"},{"id":"D000094025","term":"Post-Infectious Disorders"},{"id":"D002908","term":"Chronic Disease"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]}},"hasResults":false}